Johnson & Johnson (JNJ)
|Net Income (ttm)||17.77B|
|Ex-Dividend Date||Aug 23, 2021|
|Day's Range||160.41 - 161.81|
|52-Week Range||130.31 - 178.93|
|Price Target||188.88 (+17.1%)|
|Est. Earnings Date||Oct 19, 2021|
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the S... [Read more...]
In 2020, JNJ's revenue was $82.58 billion, an increase of 0.64% compared to the previous year's $82.06 billion. Earnings were $14.71 billion, a decrease of -2.68%.Financial Statements
According to 19 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is 188.88, which is an increase of 17.10% from the latest price.
It's highly likely.
This stock trio is perfectly positioned to help investors navigate a possible downturn.
What to expect after the FDA's approval of the J&J booster
#J&Jbooster With the FDA's advisory panel unanimously approving booster shots of the J&J vaccine two months after the first dose, Dr. Lakshman Swamy, ICU physician at Cambridge Health Alliance & Boston ...
The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporti...
We're at a very delicate time in this pandemic: FDA advisory panel member
Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA A...
NEW BRUNSWICK, N.J., Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advi...
FDA panel backs J&J Covid-19 vaccine booster shot for people 18 years and older
#J&Jvaccine Yahoo Finance's Alexis Christoforous reports the latest FDA decision on COVID-19 boosters. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb...
The advisers unanimously voted that those who got the one-dose vaccine should get a booster at least two months later.
The recommendation of the independent panel of experts is typically followed by the FDA.
Johnson & Johnson (NYSE: JNJ) put its obligations for tens of thousands of cases tying talc-based products to cancer into bankruptcy. The company hopes the action will help push a personal injury claims...
The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.
CHARLOTTE, N.C., Oct. 14, 2021 /PRNewswire/ -- Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powder...
Johnson & Johnson said on Thursday its newly created unit that was established to hold and manage claims in the Baby Powder litigation, has filed for voluntary Chapter 11 bankruptcy protection.
NEW BRUNSWICK, N.J., Oct. 14, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson...
FDA advisors prepare to vote on Moderna, J&J Covid boosters
A group of expert FDA advisors plan to meet over the coming days to discuss Moderna's and Johnson & Johnson's applications for a Covid-19 booster. CNBC's Meg Tirrell reports.
J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.
An advisory panel will review the argument for second Johnson & Johnson doses Friday.
Here are two stocks to add to your basket of buys this fall.
NEW BRUNSWICK, N.J., Oct. 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will hold a Business Review for the investment community on Thursday, November 18, 2021, in which company leaders will sh...
Johnson & Johnson (JNJ) closed the most recent trading day at $157.69, moving -1.6% from the previous trading session.